...
首页> 外文期刊>Materials science & engineering >Evaluation of the optimal dosage of BMP-9 through the comparison of bone regeneration induced by BMP-9 versus BMP-2 using an injectable microparticle embedded thermosensitive polymeric carrier in a rat cranial defect model
【24h】

Evaluation of the optimal dosage of BMP-9 through the comparison of bone regeneration induced by BMP-9 versus BMP-2 using an injectable microparticle embedded thermosensitive polymeric carrier in a rat cranial defect model

机译:使用BMP-9与BMP-2与BMP-2诱导的骨再生在大鼠颅缺陷模型中的骨再生比较评价BMP-9的最佳剂量

获取原文
获取原文并翻译 | 示例
           

摘要

Bone morphogenetic proteins (BMPs) are well known as enhancers and facilitators of osteogenesis during bone regeneration. The use of recombinant BMP-2 (rhBMP-2) in bone defect healing has drawbacks, which has driven the scouting for alternatives, such as recombinant BMP-9 (rhBMP-9), to provide comparable new bone formation. However, the dosage of rhBMP-9 is quintessential for the facilitation of adequate bone defect healing. Therefore, this study has been designed to evaluate the optimal dosage of BMP-9 by comparing the bone defect healing induced by rhBMP-9 over rhBMP-2. The chitosan (CS) microparticles (MPs), coated with BMPs, were embedded in a thermoresponsive methylcellulose (MC) and calcium alginate (Alg) based injectable delivery system containing a dosage of either 0.5 mu g or 1.5 mu g of the respective rhBMP per bone defect. A 5 mm critical-sized cranial defect rat model has been used in this study, and bone tissues were harvested at eight weeks post-surgery. The standard tools for comparing the new bone regeneration included micro computerized tomography (micro-CT) and histological analysis. A novel perspective of analyzing the new bone quality and crystallinity was employed by using Raman spectroscopy, along with its elastic modulus quantified through Atomic Force Microscopy (AFM). Results showed that the rhBMP-9 administered at a dosage of 1.5 mu g per bone defect, using this delivery system, can adequately facilitate the bone void filling with ample new bone mineralization and crystallinity as compared to rhBMP-2, thus approving the hypothesis for a viable rhBMP-2 alternative.
机译:骨形态发生蛋白(BMPS)是众所周知的骨再生期间骨质发生的增强剂和促进剂。在骨缺陷愈合中使用重组BMP-2(RHBMP-2)具有缺点,其已经为替代品(例如重组BMP-9(RHBMP-9))驱动了侦察术,以提供可比的新骨形成。然而,RHBMP-9的剂量是促进足够的骨缺损愈合的典型。因此,该研究旨在通过比较RHBMP-2上rhBMP-9诱导的骨缺陷愈合来评估BMP-9的最佳剂量。涂有BMP的壳聚糖(CS)微粒(MPS)嵌入在热致甲基纤维素(MC)和藻酸钙(藻)的基于藻酸钙(ALG)的可注射递送系统中,其包含0.5μg或1.5μg的各种RHBMP的剂量骨缺陷。在本研究中使用了5mm临界大小的颅缺损大鼠模型,手术后八周收获骨组织。用于比较新的骨再生的标准工具包括微型计算机层析成像(Micro-CT)和组织学分析。通过使用拉曼光谱法使用分析新的骨质质量和结晶度的新颖性观点,以及通过原子力显微镜(AFM)量化的弹性模量。结果表明,使用该递送系统,每骨缺损剂量为1.5μg施用的RHBMP-9,可以充分促进与RHBMP-2相比的充足新的骨矿化和结晶度的骨空隙填充,从而批准假设可行的RHBMP-2替代方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号